OTCMKTS:AITB - AIT Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.74 +0.05 (+1.07 %) (As of 01/21/2019 04:00 PM ET)Previous Close$4.69Today's Range$4.70 - $4.7452-Week Range$2.05 - $5.49Volume1,800 shsAverage Volume6,342 shsMarket Capitalization$40.45 millionP/E Ratio-1.57Dividend YieldN/ABeta-0.59 ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York. Receive AITB News and Ratings via Email Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:AITB Previous Symbol CUSIPN/A Webwww.ait-therapeutics.com Phone972-8684-3313Debt Debt-to-Equity RatioN/A Current Ratio4.03 Quick Ratio4.03Price-To-Earnings Trailing P/E Ratio-1.57 Forward P/E Ratio-3.67 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-18,040,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-168.23%Miscellaneous Employees12 Outstanding Shares8,530,000Market Cap$40.45 million OptionableNot Optionable AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions What is AIT Therapeutics' stock symbol? AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB." How were AIT Therapeutics' earnings last quarter? AIT Therapeutics Inc (OTCMKTS:AITB) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.32. View AIT Therapeutics' Earnings History. When is AIT Therapeutics' next earnings date? AIT Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for AIT Therapeutics. Has AIT Therapeutics been receiving favorable news coverage? Headlines about AITB stock have been trending very positive on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are some of AIT Therapeutics' key competitors? Some companies that are related to AIT Therapeutics include T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), RA Medical Systems (RMED), STRATA Skin Sciences (SSKN), Endologix (ELGX), iCAD (ICAD), Alphatec (ATEC), Apollo Endosurgery (APEN), Motus GI (MOTS), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Repro-Med Systems (REPR), Pro-Dex (PDEX) and CAS Medical Systems (CASM). Who are AIT Therapeutics' key executives? AIT Therapeutics' management team includes the folowing people: Mr. Steven Adam Lisi, CEO & Chairman (Age 48)Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)Mr. Douglas J. Beck, Chief Financial Officer (Age 58)Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory BoardDr. Giora Davidai M.D., Chief Medical Officer How do I buy shares of AIT Therapeutics? Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AIT Therapeutics' stock price today? One share of AITB stock can currently be purchased for approximately $4.74. How big of a company is AIT Therapeutics? AIT Therapeutics has a market capitalization of $40.45 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe. What is AIT Therapeutics' official website? The official website for AIT Therapeutics is http://www.ait-therapeutics.com. How can I contact AIT Therapeutics? AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313. MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 63 (Vote Outperform)Underperform Votes: 77 (Vote Underperform)Total Votes: 140MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is Compound Interest?